Vanda amends bylaws with clarifications on special meetings, advance notice, and director nominations

Vanda Pharmaceuticals Inc.

Board approved amended bylaws effective October 2, 2024; changes include clarifying special meeting scope to agenda topics only.
Advance notice provisions for shareholder nominations and proposals expanded with additional disclosure requirements.
Adjournment process clarified for meetings relying on remote communication due to technical failure.
Proxy solicitation requirements and director candidate standards spelled out more explicitly.
Special board meetings may now be called by a majority of directors; officer definition narrowed to exclude non-officer title holders.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Vanda Pharmaceuticals Inc.: Amended and restated bylaws with changes to special meeting business scope, advance notice disclosure, meeting adjournment, proxy solicitation, director candidate requirements, and other clarifying updates (effective 2024-10-02).

Change: bylaw amendment
Effective: 2024-10-02

Exact text from the filing

On October 2, 2024, the Board of Directors (the "Board") of Vanda Pharmaceuticals Inc. (the "Company") approved an amendment and restatement of the Company’s amended and restated bylaws (as so amended and restated, the "Amended and Restated Bylaws"), effective immediately.

View on SEC.gov

Browse all governance changes →

Vanda Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-232306

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.